Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise
Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly…
Flare Research Warns 1 in 5 Infostealer Infections Could Yield Enterprise Credentials in 2026
Web-based tool makes it easier to design advanced materials
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets